21,011 Shares in Apellis Pharmaceuticals, Inc. $APLS Bought by Corton Capital Inc.

Corton Capital Inc. purchased a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 21,011 shares of the company’s stock, valued at approximately $364,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Assetmark Inc. boosted its stake in Apellis Pharmaceuticals by 3,938.7% in the first quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock worth $27,000 after purchasing an additional 1,221 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Apellis Pharmaceuticals by 80.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after purchasing an additional 855 shares during the last quarter. GF Fund Management CO. LTD. boosted its position in shares of Apellis Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock worth $70,000 after purchasing an additional 573 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Apellis Pharmaceuticals by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock worth $84,000 after buying an additional 655 shares during the period. Finally, Amalgamated Bank raised its stake in Apellis Pharmaceuticals by 12.0% during the 2nd quarter. Amalgamated Bank now owns 8,111 shares of the company’s stock worth $140,000 after buying an additional 866 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on APLS shares. TD Cowen lowered their target price on Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday. Wall Street Zen upgraded Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. JPMorgan Chase & Co. boosted their price objective on Apellis Pharmaceuticals from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday, August 4th. Cantor Fitzgerald lifted their price target on shares of Apellis Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Finally, Raymond James Financial lowered their price target on shares of Apellis Pharmaceuticals from $52.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, August 1st. Ten research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $33.50.

Apellis Pharmaceuticals Price Performance

Apellis Pharmaceuticals stock opened at $21.47 on Monday. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $35.72. The company’s 50 day moving average price is $25.51 and its two-hundred day moving average price is $21.74. The company has a quick ratio of 3.16, a current ratio of 3.77 and a debt-to-equity ratio of 2.90. The stock has a market cap of $2.72 billion, a P/E ratio of 69.26 and a beta of 0.70.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 24.58%. The company had revenue of $458.58 million during the quarter, compared to analyst estimates of $364.58 million. During the same quarter last year, the business posted ($0.46) EPS. Apellis Pharmaceuticals’s quarterly revenue was up 133.0% compared to the same quarter last year. On average, equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 31,092 shares of the business’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $23.72, for a total transaction of $737,502.24. Following the transaction, the director owned 3,837 shares in the company, valued at $91,013.64. The trade was a 89.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Cedric Francois sold 175,037 shares of the business’s stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $28.19, for a total transaction of $4,934,293.03. Following the transaction, the chief executive officer owned 357,909 shares in the company, valued at $10,089,454.71. This represents a 32.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 312,921 shares of company stock worth $8,490,866 over the last ninety days. Corporate insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).